MEDINDIA
English
हिन्दी
Español
français
中文
(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO)
Scott Garrett, Beckman Coulter's president and chief executive officer,said, "We are enthusiastic about the opportunity to add Dako's MoFlo XDPhigh-performance sorter, the gold standard for cell sorting, and the highlycapable nine-color CyAn research flow cytometer to our existing portfolio ofcytometry instruments. This transaction allows us to offer a morecomprehensive range of research solutions to our customers."
Dako's president and CEO, Patrik Dahlen, said, "This action reinforces ourstrategic intent to create a more focused business in anatomic pathology andtissue-based cancer diagnostics. We believe our flow cytometry instrumentationproducts are an excellent match for Beckman Coulter and will achieve evengreater success when combined with the company's existing flow cytometryinfrastructure and reputation for quality, service and support."
Dako's flow cytometry instrument business workforce of almost 200 peopleincludes sales, marketing, research, manufacturing and administrativepersonnel. Flow cytometry is used to analyze cells in blood and other fluidsfor both research applications and diagnosis of diseases such as leukemia,lymphoma and HIV.
Garrett added, "I want to welcome the talented people transferring to usfrom Dako. We see significant opportunities for Beckman Coulter in flowcytometry and continue to expand our investment in this fast-growing marketsegment."
The transaction is expected to close by the end of the year. Moreinformation about the transaction will be available during Beckman Coulter's2007 Annual Business Review meeting on December 11. Contact Investor Relationsfor details.
About Dako
Dako, which is headquartered in Denmark, strives to improve tissue-basedcancer diagnostics focusing on the workflow in the pathology laboratory. Thecompany develops and markets instruments, reagents and software that willreduce time from biopsy to diagnosis, improve the quality and reliability ofdiagnosis, and increase efficiency in the lab. For information, visithttp://www.dako.com.
About Beckman Coulter, Inc.
Based in Fullerton, California, Beckman Coulter develops, manufactures andmarkets products that simplify, automate and innovate complex biomedical tests.More than 200,000 Beckman Coulter systems operate in laboratories around theworld, supplying critical information for improving patient health andreducing the cost of care. Recurring revenue consisting of supplies, testkits, service and operating-type lease payments represents more than75 percent of the company's 2006 annual revenue of $2.53 billion. For moreinformation, visit http://www.beckmancoulter.com.
Forward Looking Statements
This press release contains forward-looking statements, includingstatements regarding the contribution of the acquisition to Beckman Coulter'sR&D and product development capability. These statements are based on currentexpectations and assumptions. Actual results could differ materially fromthose anticipated by these forward-looking statements as a result of a numberof factors, some of which may be beyond Beckman Coulter's control. BeckmanCoulter disclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information, futureevents or otherwise, except as required by law.Highly-Regarded Research Flow Cytometry Portfolio Targe
